| TOR signaling in growth and metabolism S Wullschleger, R Loewith, MN Hall Cell 124 (3), 471-484, 2006 | 6984 | 2006 |
| Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control R Loewith, E Jacinto, S Wullschleger, A Lorberg, JL Crespo, D Bonenfant, ... Molecular cell 10 (3), 457-468, 2002 | 2341 | 2002 |
| A colorectal cancer classification system that associates cellular phenotype and responses to therapy A Sadanandam, CA Lyssiotis, K Homicsko, EA Collisson, WJ Gibb, ... Nature medicine 19 (5), 619-625, 2013 | 1088 | 2013 |
| Identification of Protor as a novel Rictor-binding component of mTOR complex-2 LR Pearce, X Huang, J Boudeau, R Pawłowski, S Wullschleger, M Deak, ... Biochemical Journal 405 (3), 513-522, 2007 | 637 | 2007 |
| Important role of the LKB1–AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice X Huang, S Wullschleger, N Shpiro, VA McGuire, K Sakamoto, YL Woods, ... Biochemical Journal 412 (2), 211-221, 2008 | 484 | 2008 |
| Molecular organization of target of rapamycin complex 2 S Wullschleger, R Loewith, W Oppliger, MN Hall Journal of Biological Chemistry 280 (35), 30697-30704, 2005 | 321 | 2005 |
| Tor2 directly phosphorylates the AGC kinase Ypk2 to regulate actin polarization Y Kamada, Y Fujioka, NN Suzuki, F Inagaki, S Wullschleger, R Loewith, ... Molecular and cellular biology, 2005 | 274 | 2005 |
| Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney LR Pearce, EM Sommer, K Sakamoto, S Wullschleger, DR Alessi Biochemical Journal 436 (1), 169-179, 2011 | 232 | 2011 |
| A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics A Sadanandam, S Wullschleger, CA Lyssiotis, C Grötzinger, S Barbi, ... Cancer discovery 5 (12), 1296-1313, 2015 | 165 | 2015 |
| Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance JR Bayascas, S Wullschleger, K Sakamoto, JM Garcia-Martinez, ... Molecular and cellular biology 28 (10), 3258-3272, 2008 | 162 | 2008 |
| Phenformin as prophylaxis and therapy in breast cancer xenografts M Appleyard, KE Murray, PJ Coates, S Wullschleger, SE Bray, ... British journal of cancer 106 (6), 1117-1122, 2012 | 116 | 2012 |
| PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells L Codarri Deak, V Nicolini, M Hashimoto, M Karagianni, PC Schwalie, ... Nature 610 (7930), 161-172, 2022 | 115 | 2022 |
| Regulation of the polarity kinases PAR-1/MARK by 14-3-3 interaction and phosphorylation O Göransson, M Deak, S Wullschleger, NA Morrice, AR Prescott, ... Journal of cell science 119 (19), 4059-4070, 2006 | 75 | 2006 |
| Role of TAPP1 and TAPP2 adaptor binding to PtdIns(3,4)P2 in regulating insulin sensitivity defined by knock-in analysis S Wullschleger, DH Wasserman, A Gray, K Sakamoto, DR Alessi Biochemical Journal 434 (2), 265-274, 2011 | 65 | 2011 |
| Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation A Sadanandam, SS Sidhu, S Wullschleger, S Singh, ML Varney, CS Yang, ... British journal of cancer 107 (3), 501-507, 2012 | 57 | 2012 |
| Effect of PI3K-and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice JM Garcia-Martinez, S Wullschleger, G Preston, S Guichard, S Fleming, ... British journal of cancer 104 (7), 1116-1125, 2011 | 55 | 2011 |
| Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells X Jiang, S Zhu, TS Panetti, ME Bromberg Thrombosis and haemostasis 100 (07), 127-133, 2008 | 52 | 2008 |
| Interaction of TAPP adapter proteins with phosphatidylinositol (3, 4)‐bisphosphate regulates B‐cell activation and autoantibody production I Landego, N Jayachandran, S Wullschleger, T Zhang, IW Gibson, A Miller, ... European journal of immunology 42 (10), 2760-2770, 2012 | 44 | 2012 |
| Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages M Tichet, S Wullschleger, A Chryplewicz, N Fournier, R Marcone, ... Immunity 56 (1), 162-179. e6, 2023 | 42 | 2023 |
| A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics … A Sadanandam, S Wullschleger, CA Lyssiotis, C Grötzinger, S Barbi, ... CD-15-0068.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 2015 | 39 | 2015 |
